IL-13 Receptor α2 Selectively Inhibits IL-13-Induced Responses in the Murine Lung
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
IL-13 is a critical cytokine at sites of Th2 inflammation. In these locations it mediates its effects via a receptor complex, which contains IL-4Rα and IL-13Rα1. A third, high-affinity IL-13 receptor, IL-13Rα2, also exists. Although it was initially felt to be a decoy receptor, this has not been formally demonstrated and the role(s) of this receptor has recently become controversial. To define the role(s) of IL-13Rα2 in IL-13-induced pulmonary inflammation and remodeling, we compared the effects of lung-targeted transgenic IL-13 in mice with wild-type and null IL-13Rα2 loci. We also investigated the effect of IL-13Rα2 deficiency on the OVA-induced inflammatory response. In this study, we show that in the absence of IL-13Rα2, IL-13-induced pulmonary inflammation, mucus metaplasia, subepithelial fibrosis, and airway remodeling are significantly augmented. These changes were accompanied by increased expression and production of chemokines, proteases, mucin genes, and TGF-β1. Similarly, an enhanced inflammatory response was observed in an OVA-induced phenotype. In contrast, disruption of IL-13Rα2 had no effect on the tissue effects of lung-targeted transgenic IL-4. Thus, IL-13Rα2 is a selective and powerful inhibitor of IL-13-induced inflammatory, remodeling, and physiologic responses in the murine lung.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fibrotic disease and the TH1/TH2 paradigm
Wynn, T. A. (2004) · Nature Reviews Immunology · doi:10.1038/nri1412 · Cited by 1,765 · cited 1×
“These findings appear to conflict with our findings and those by others in murine schistosomiasis models (38, 42, 57) that IL13R 2 inhibits TGF- 1 production and tissue fibrosis.”
ResultLee, C. G., Homer, R. J., Zhu, Z., Lanone, S., Wang, X., Koteliansky, V., Shipley, J. M., Gotwals, P., Noble, P., Chen, Q., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.809 · Cited by 940 · cited 3×
“Previous studies from our laboratory demonstrated that IL-13 induces pulmonary fibrosis, in part, via its ability to induce and activate TGF- 1 and that this activation is partially mediated by matrix metalloproteinase (MMP) 9 (1, 32).”
BackgroundSelf-citationInterleukin‐13 in asthma pathogenesis
Wills‐Karp, M. (2004) · Immunological Reviews · doi:10.1111/j.0105-2896.2004.00215.x · Cited by 683
Chiaramonte, M. G., Donaldson, D. D., Cheever, A. W., & Wynn, T. A. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7325 · Cited by 603 · cited 2×
“These findings appear to conflict with our findings and those by others in murine schistosomiasis models (38, 42, 57) that IL13R 2 inhibits TGF- 1 production and tissue fibrosis.”
BackgroundResultNew insights into the pathogenesis of asthma
Elias, J. A., Lee, C. G., Zheng, T., Ma, B., Homer, R. J., & Zhu, Z. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17748 · Cited by 407
Self-citationIL-13 Activates a Mechanism of Tissue Fibrosis That Is Completely TGF-β Independent
Kaviratne, M., Hesse, M., Leusink, M., Cheever, A. W., Davies, S. J., McKerrow, J. H., Wakefield, L. M., Letterio, J. J., & Wynn, T. A. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.6.4020 · Cited by 370 · cited 1×
“Studies in a variety of systems have demonstrated that IL-13 is a major mediator of these fibrotic responses (42, 51, 56).”
Background
Cited by
Integrating mechanisms of pulmonary fibrosis
Wynn, T. A. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20110551 · Cited by 1,274
Type 2 immunity in tissue repair and fibrosis
Gieseck, R. L., Wilson, M. S., & Wynn, T. A. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.90 · Cited by 1,055
Pulmonary fibrosis: pathogenesis, etiology and regulation
Wilson, M. S., & Wynn, T. A. (2009) · Mucosal Immunology · doi:10.1038/mi.2008.85 · Cited by 822
Type 2 cytokines: mechanisms and therapeutic strategies
Wynn, T. A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3831 · Cited by 678
Emerging Functions of Amphiregulin in Orchestrating Immunity, Inflammation, and Tissue Repair
Zaiss, D. M. W., Gause, W. C., Osborne, L. C., & Artis, D. (2015) · Immunity · doi:10.1016/j.immuni.2015.01.020 · Cited by 638
IL-4 and IL-13 signaling in allergic airway disease
Gour, N., & Wills-Karp, M. (2015) · Cytokine · doi:10.1016/j.cyto.2015.05.014 · Cited by 490
Commentary: IL-4 and IL-13 receptors and signaling
McCormick, S. M., & Heller, N. M. (2015) · Cytokine · doi:10.1016/j.cyto.2015.05.023 · Cited by 317
IL-13 in asthma and allergic disease: Asthma phenotypes and targeted therapies
Ingram, J. L., & Kraft, M. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.06.034 · Cited by 253
Popovic, B., Breed, J., Rees, D. G., Gardener, M. J., Vinall, L. M. K., Kemp, B., Spooner, J., Keen, J., Minter, R., Uddin, F., et al. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.12.005 · Cited by 198
Strategies targeting the IL-4/IL-13 axes in disease
May, R. D., & Fung, M. (2015) · Cytokine · doi:10.1016/j.cyto.2015.05.018 · Cited by 166
Mechanisms of Oncostatin M-Induced Pulmonary Inflammation and Fibrosis
Mozaffarian, A., Brewer, A. W., Trueblood, E. S., Luzina, I. G., Todd, N. W., Atamas, S. P., & Arnett, H. A. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.10.7243 · Cited by 153
Metadata
- Authors
- Zheng, T., Liu, W., Oh, S.-Y., Zhu, Z., Hu, B., Homer, R. J., Cohn, L., Grusby, M. J., & Elias, J. A.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-01-01
- Volume
- 180
- Issue
- 1
- Pages
- 522-529
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1564761922
- Cited by
- 86
- References
- 6
- FWCI
- 4.22
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.